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POSITIVE AND NEGATIVE SYMPTOMS QUESTIONNAIRE-REVISED

EMENA BELT

ABSTRACT

Previously, Iancu and Poreh (2005) constructed a measure for the assessment of
Positive and Negative Symptoms Questionnaire (PNS-Q). This self-report measure was
designed to clarify the insight of schizophrenic patients as well as be used to examine
changes in their presenting symptoms across time. This measure was used in a variety of

studies with mixed results. The current study aimed to update the PNS-Q questions,
improve the content validity, and provide preliminarily psychometric properties of the

revised scale. Additionally, the study examined the construct validity of the revised scale
by correlating with the McEvoy’s Vignettes (McEvoy, 1993), a measure of insight and

acute psychopathology. The study shows that there was a linear relationship between
subscales Bizarre disorganization, Alogia, Avolition, and the McEvoy scale. The study
also provides partial support for the construct validity of the new measures with a high
internal consistency of the overall measure at .928. Additionally, there was partial
support in obtaining distinct positive and negative components within the scale. In sum,

this study provides some preliminary evidence regarding the reliability and validity of the

revised. However, due to the small sample size, lack of diversity, and lack of participates

with the diagnosis of schizophrenia additional research is needed.

iii

TABLE OF CONTENTS

Page
ABSTRACT .................................................................................................................. iii
LIST OF TABLES ......................................................................................................... vi
LIST OF FIGURES ....................................................................................................... vii

CHAPTER
I. INTRODUCTION ................................................................................................ 3

1.1

Diagnosing Schizophrenia - A HistoricalBackground.................................3

1.2

Positive and Negative SymptomOutcome Studies..................................... 5

1.3

Criticisms of current measures..................................................................... 6

1.4 Insight in Schizophrenia..............................................................................8
1.5

Revision of the PNS-QR............................................................................. 9

II. METHODS & MEASURES ............................................................................. 11

2.1. The Positive and Negative Questionnaire-Revised (PNS-QR) ................. 11
2.2. McEvoy Vignettes..................................................................................... 13
2.3. Procedure ................................................................................................... 13
2.4. Participants................................................................................................. 14
III. RESULTS ......................................................................................................... 15

3.1. Analysis...................................................................................................... 15
3.2. Reliability................................................................................................... 15
3.3. Construct Validity ...................................................................................... 16
IV. DISCUSSION.................................................................................................... 22

REFERENCES .............................................................................................................. 26

iv

35

APPENDIX

v

LIST OF TABLES

Table

Page

1. Demographics .................................................................................................... 14
2. Reliability............................................................................................................ 16

3. Principal Component Analysis .......................................................................... 17
4. Independent Samples Test.................................................................................. 17

5. Independent Samples Test- Area Under the Curve............................................. 18

6. Correlation of Subscales ..................................................................................... 19
7. Multiple Regression Between the PNS-QRand McEvoy Scales .......................20
8. Excluded variables............................................................................................. 21

vi

LIST OF FIGURES

Figure

Page

1. SAPS and SANS classifications .......................................................................... 12

vii

CHAPTER I

INTRODUCTION

Schizophrenia is characterized as a severe mental disorder with an international
prevalence of 0.7% (Mattila, 2015). When considering the rate of diagnosis, one hundred
thousand people around the world are diagnosed annually (Insel, 2010). While only

comprising a small subset of the population, it is visible across all countries and cultures.
Its severe psychopathology and incessant chronic deterioration can have lifelong

implications on an individual’s life without early intervention and treatment. Onset
normally occurs in late teens to mid-twenties for both males and females but is more

prevalent in males (Messias, 2007). The etiology of schizophrenia is not known but there
are risk factors that make some populations more susceptible to have a diagnosis of this
disorder. Some common risk factors can be ethnicity, especially those of African descent,

as well as those located in urban environments (Messias, 2007). According to the DSM-5,

diagnosis is contingent on having at least 2 of the following symptoms for at least 6
months: "delusions, hallucinations, disorganized speech, grossly disorganized or
catatonic behavior. This also includes negative symptoms such as alogia, avolition, and

anhedonia" (American Psychiatric Association, 2013), with the requirement that one of
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the symptoms must be either delusions, hallucinations, or disorganized speech. In

addition to symptomatology, there must be dysfunction in their social life or work
environment (American Psychiatric Association, 2013).

In its mild forms, patients with Schizophrenia can often lead regular lives as 20
25% of those diagnosed achieve remission (Brady, 2004). Patients with more severe and

persistent features exhibit deficits in areas related to planning daily schedules, regulation

of social behavior, and emotionality (Semkovska et al, 2004). Impulsivity, rationality,
and linear organization of thoughts can become more difficult as the disorder progresses.

Memory loss as well as deficiencies in verbal fluency are also common (Orellana and

Slachevsky, 2013). Besides cognition, schizophrenia is also characterized by neurological
soft signs that can affect both fine and gross motor skills. Symptoms can include rigidity,
gait imbalances, and tremors (Varambally et al., 2012). Tardive Dyskinesia, a side effect

of second generation antipsychotics, is a well-known indicator that causes stiffening of
the body and or uncontrolled actions like twisting and writhing (Correll & Schenk, 2008).

When considering disease management, medications are commonly used. Secondgeneration antipsychotics are often preferred due to their lack of side effects. In cases that

patients do not respond to normally prescribed medicines like typical and atypical
antipsychotics, they might be considered treatment-resistant (Conley & Buchanan, 1997).

Treatment-resistant schizophrenia (TRS) can lead to decreased quality of life as there are

not many alternatives (Kinon, 2019). When considering the medicinal improvements of

schizophrenia, it is important to evaluate positive and negative symptoms. The use of

antipsychotics in the treatment of schizophrenia increased as researchers found that
positive symptoms could be mediated by the drugs (Mitra, 2016). This caused a search
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for a medication that would quell both positive and negative symptoms, allowing for an

increased quality of life. To understand the motivations for this quest, it is important to

recognize the evolution of schizophrenia and the importance of positive and negative
symptoms.

Diagnosing Schizophrenia - A Historical Background

The embodiment of schizophrenia has taken many forms throughout history. The
initial nosology of schizophrenia was labeled "Dementia praecox” by Emil Kraepelin

(Andreasen, 1995). Through his observations, he established “9 clinical forms” or
categorizations. While he did not explicitly define his impressions into positive and

negative symptoms, he founded the initial concepts that are still present in current
symptomatology (Jablensky, 2010).
As the concept of Schizophrenia was developing, Hughlings Jackson (1931) was

the first to define positive and negative symptoms. He distinguished positive symptoms
as abnormalities within the cognitive state and believed that negative symptoms stemmed

from a disease state. This initial concept impacted the research on schizophrenia decades

later. In 1980, Crow was especially enthralled by the idea of positive and negative
symptoms and how positive symptoms could be indicative of a chemical imbalance, a
popular theory at the time (Beck et al., 2009). Notably, Andreasen (1982) noticed through

clinical impressions that many patients had both positive and negative symptomology and
suggested a mixed category. There are also some suggestion that positive and negative

symptoms are not distinct to schizophrenia but may be present on a continuum between

clinical and non-clinical patients (David, 2010). Kaiser (2011) found that negative
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symptoms were also found in relatives of patients with schizophrenia, suggesting genetic
etiologies.

In the current day, the concept of positive and negative symptoms is stable. The
Diagnostic and Statistical Manual 5th edition (DSM-V) defines positive symptoms as
hallucinations, thought disorders, disorganized speech, disorganized behavior, delusions,

and movement disorders (American Psychiatric Association (APA), 2013). These

symptoms can be defined as abnormal and are not normally seen. In comparison,

negative symptoms are also abnormal but represent a lack of normal behavior. Negative
symptoms can include alogia, flat affect, avolition, anhedonia, and loss of attention
(APA, 2013).

In literature, many have suggested models to explain the causes and differences
for both positive, negative, and mixed symptoms. Popular models surrounding positive
symptoms aim to understand the proposed development of hallucinations and paranoid
delusions. The ABC model for psychosis (Ellis & Harper, 1961) consists of 3

components: activating events, beliefs, and consequences. It specifically addresses how a

patient’s life status and personal beliefs may contribute to the manifestation of voices and

delusions (Morrison, 2002). Another model proposed similar themes for the evaluation
of auditory-verbal hallucinations. Bentall and Fernyhough (2008) discussed a model that

attributes these positive symptoms to “poor source monitoring.” This model focuses on
how misperception of motivations from oneself and others can allow for a manifestation
of unfounded beliefs and intrusive thoughts. Negative symptoms are an area of interest

due to the limitations in improvements and treatment involving those symptoms. Due to
these limitations, models theorize that negative symptoms are a mechanism by the body
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to protect mental reserves and to safeguard from negative social consequences of

schizophrenia (Rector et al., 2005). There is some suggestion for a two factor model for
negative symptoms. With the recognition that negative symptoms are not one dimension
but rather should be separated by avolition related symptoms and poor emotional

expression symptoms (Jang et al., 2016).
Positive and Negative Symptom Outcome Studies

The evaluation of positive and negative symptoms is important when considering
patient outcomes. The state of a patient’s premorbid functioning can be an indicator of
either negative or positive symptoms. In 1982, Andreasen discussed a relationship

between negative symptoms and premorbid functioning. This idea was further evaluated

by Addington and Addington (1993). They found that males had significantly worse
premorbid functioning compared to females. Additionally, a longitudinal study found that
those with positive symptoms had a significant reduction of symptomatology over time in

contrast with patients demonstrating negative symptoms. Additionally, there was a
significant difference in the amount of time spent in treatment with those displaying
negative symptoms (Austin et al, 2015).
Functional and structural brain imaging techniques have become an integral part

of the assessment of positive and negative symptoms. There is conflicting information
available about the usefulness of these techniques. Karlsgodt and colleagues (2010)
suggest that anatomical brain anomalies specific to schizophrenia patients can be

revealed through brain imaging, focusing on the temporal and frontal lobe. Loss of brain
matter in these areas can be associated with deficits of semantic, episodic, and short-term
memory, impulsivity, and other cognitive domains (Karlsgodt et al., 2010). Large
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ventricles while not unique to schizophrenia patients is a common feature and can also

explain cognitive deficits (Kasai et al., 2003). In 1985, Andreasen explained that common
features characterized by positive symptoms may not be shown through functional or
structural imaging techniques. If anything, subjects were shown to have slightly smaller
ventricles. However, when considering negative symptoms, there appeared to be common

brain abnormalities listed in the previous article, suggesting that negative symptoms are

related to left hemisphere abnormalities (Andreasen, 1985).

While there are certain benefits to using imaging techniques, it’s not always
practical in outpatient or inpatient clinical settings. While the visual impact can be
reassuring to patients and can help detect other neurological anomalies, it may not be an
effective measure due to insurance costs, time, and lack of qualified personnel regarding

patient load (Albon et al., 2008). Some practices may order Magnetic resonance imaging
and Computed tomography scans to rule any neurological damage or search for organic
diseases that may be the cause for underlying psychosis but that is not always pertinent.

Sommer et al. (2013) found that MRIs only found "relevant pathology" in 11% of the

MRIs, implying that functional imaging is not an end-all source for those seeking a
diagnosis. Patients may then be referred to qualified personnel to be assessed for their

current mental functions.
Criticisms of Current Measures
While the number of those afflicted with schizophrenia is low, the severity of the

condition requires attention by the medical and psychological community. A common
method to attain a positive diagnosis of schizophrenia is through an assortment of

psychological assessments, however, these batteries while comprehensive can be time
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consuming and require advanced clinicians to be familiar enough with these batteries to
perform them (Harvey et al., 2001). The most cited and popular measures to assess for

positive and negative symptoms are the Scale for the Assessment of Positive Symptoms

(SAPS), Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1980),
and the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987). A frequent
criticism of SAPS and SANS is that by requiring two separate measures to give an
accurate understanding of both positive and negative symptoms, it is not as helpful nor
effective as would one encompassing measure. The PANSS is considered the most robust

measure of use due to its ability to track patients throughout treatment (Kumari et al.,
2017). While these measures are the standard in clinical research, their use in clinical
patient settings has been limited. This is due in part to their lengthy administration time;

the PANSS has an administration time of 45-50 minutes, the SAPS has an administration

of 30 mins, and the SANS has an undefined administration time (Kumari et al., 2017).
Ultimately in patient settings, evaluation needs to be streamlined to meet the needs of as

many patients as possible in the least amount of time.

This study is proposing a different assessment technique that would allow for a
self- report measure that would be beneficial to both patients and clinicians. The

questions would encompass symptomatology such as positive and negative symptoms
and motor deficits. This scale is designed with clinicians in mind. It would allow for a
further understand of premorbid functioning. As well as reduce the economic burden on

individuals by decreasing the need for expensive and unnecessary tests.
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Insight in Schizophrenia

Similar assessments like the one this study is proposing have been overlooked in
the past due to a presumed lack of insight within patients with schizophrenia. "Insight"
describes the awareness of illness and recognition for the need for treatment (Lysaker &

Bell, 1994). A popular scale to assess for insight in patients is the "Scale to Assess
Unawareness of Mental Disorder.” The major components of insight that the scale
assesses are awareness of symptoms, illness, and social consequences. While individuals
with schizophrenia are typically characterized as having little to no insight, Sevy (2004)

found that "the percentage of patients having a lack of awareness was 58.2% for
symptoms, 32.7% for illness, 41.8% for social consequences and 18.4% for treatment
response.” This is an indicator that insight can exist on a continuum rather than as a

bimodal trait.
Understanding how a patient views their condition can allow further
understanding of future treatment. Lack of insight can be an indicator of poor medication

adherence, resistance to psychological treatment, and low therapeutic alliance (Bota et
al., 2006). While there are conflicting studies, the consensus in the literature is that 50 -

80% of patients have inhibited insight (Bastiaens & Agarkar, 2014). It is not fully
understood how insight deteriorates or how it fluctuates (Bota et al., 2006). It is often

thought that poor insight acts as a psychological defense against denial and
neurocognitive deficits. Other studies have theorized that poor insight could be a coping

mechanism that allows the patient to survive and complete daily tasks amidst stigma
derived from their disorder (Lysaker & Bell, 1994). Additionally, a 2006 study indicated
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that higher insight was strongly correlated with increased levels of depression, paranoia,

suicidality, and anxiety among males and females (Bota et al., 2006).
There is value in assessing individuals with schizophrenia through self-report
measures. For the purpose of this study, it is important to understand the validity of self

report assessments with patients with psychosis. With any self-report assessments, there
can be effects of positive impression management, performance validity, and effects of

symptomatology (Bell et al., 2006). A 2007 study looked into the validity of self
assessment reports in patients with psychosis, finding patients were able to accurately

reflect on their positive symptoms, agreeableness, and neuroticism. However, patients
were not reliable in reporting their social functioning (Bell et al, 2007). This allows us to
understand that while not every aspect can be measured by self-report, there is efficacy in

having a self-report measure.

Revision of the PNS-Q
The Positive and Negative Symptoms-Questionnaire (PNS-Q) was originally

developed to address the above limitations (Iancu et al., 2005). It possesses high validity
with the positive effect measure, the Scale for the Assessment of Positive Symptoms,

SAPS (Andreasen, 1983), and McEvoy Scale (McEvoy et al, 1993). But it was not shown
to be highly correlated with negative affect scales such as the Scale for Assessment of
Negative Symptoms, SANS (Andreasen, 1984). It also attained high internal consistency

for both of positive and negative components. It originally consisted of 68 questions and

in a later version includes an informant section for the family to further assess insight.
The present study had three aims in addition to revising PNS-Q and adjusting the scale

questions. The first aim intended to assess the reliability of the total scale as well as the
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subscales. Assessing the reliability of the subscales was not done in the past study. The
second aim assessed if there were distinct positive and negative components of the scale.

The last aim intended to examine if there is a positive linear relationship between the
McEvoy scale and the PNS-QR subscales. The relationship might be able to allow us to

know which subscales are valuable to clinicians as far as patient insight.
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CHAPTER II

METHODS & MEASURES

The Positive and Negative Questionnaire-Revised (PNS-QR)

Each question of the PNS-QR was assessed and compared to other Schizophrenia Scales.
Specifically, the questions were reformed to be consistent with SAPS and SANS. The

SAPS and SANS both have clear classifications and subclassifications for each
assessment. The classifications for SAPS are Hallucinations, Delusions,
Bizarre/Disorganized Behavior, Thought Disorder, and Inappropriate Affect (Andreasen,

1985), whereas the classifications for SANS consists of Affect Flattening, Alogia,
Avolition, Anhedonia, and Attention (Andreasen 1995). These classifications are
presented in a visual format below in Figure 1.
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Figure 1: SAPS and SANS Classifications

When considering item generation, additional schizophrenia measures were
assessed, specifically using the Scale for the Assessment of Schizotypal Personality

developed by Raine (1991). While not specifically formulated for schizophrenia, the SPQ
was derived from the SANS, Schedule for Affective Disorders and Schizophrenia
(SADS) (Endicott and Spitzer 1978), DSM-II-R, and other similar measures. These

measures are consistent with the major and minor classifications of SAPS and SANS as
they include questions surrounding speech patterns, behavior, beliefs, awareness. The
Brief Impression Questionnaire modeled from the PANSS (Lanser et al. 2018) was also

included as it is a measure that predicts social performance in schizophrenia patients.
The final revised version of the PNS-QR includes 73 questions omitting the McEvoy
Vignettes. It is estimated that the questionnaire takes 20-25 minutes to complete for the
average participant.

The 73 items were separated into subscales. The subscales represented the
subcategories of the SAPS and SANS. Positive subscales were Hallucinations,
Delusions, Thought Disorder, Bizarre Disorganization, and Inappropriate Affect.
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Negative subscales included Alogia, Affective Flattening Blunting, Avolition, and

Anhedonia. Subscales were developed using total score function with appropriate
questions.

McEvoy Vignettes
At the end of the questionnaire 8 vignettes originally developed by McEvoy

(1993) were presented. This measure was included because of its self-report nature
related to insight. While this scale is not a direct measure of insight, it allows clinicians to
assess patients' understanding and ability to accurately assess the problems presented in
the vignettes. The original vignettes have prompts related to positive, negative, and manic

symptoms (McEvoy et al., 1995). For this reason, this scale was selected as a comparable
measure to the revised scale.

Procedure

This study aimed to reach individuals that self-reported being diagnosed with
Schizophrenia, Schizoaffective, Bipolar Disorder, Borderline personality disorder, and/or
Depression. Individuals with no self-identifying mental health history were also
examined. After opting into the study, participants were given a consent form to

understand the purpose of the study as well as the risks*. Following the consent form,
emails were sent allowing directing participants to SurveyGizmo.com. After receiving the

email, subjects were tasked to answer the set of 73 questions which included a 4 point

Likert scale. Answer options included False, Mainly False, Mainly True, and True.
*Please see the appendix for reference.
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Participants
For the purpose of this study, all participants were required to be at least 18 years

old. Volunteers were given the opportunity to participate in this study through
Researchmatch.org. Research Match is an online database that recruits participants in the
United States for health-related studies. It should be noted that the participants who use
this website as well as those included in the study are not random as they voluntarily

chose to participate in the study. The participants were then redirected to survey gizmo to
take the questionnaires. The initial sample of the study consisted of 76 participants.

Regarding data screening, 14 were removed from the study if they had more than 90%

incomplete forms. A total of 62 participants were included in the final analyses of this
study. The ages of the participants ranged from 18 to 74 with an average age of 41.81
(SD=13.99) and a level of education ranging from High School to Doctorate Level.

Table 1: Demographics
Background Variables
Gender (n)
% Male
% Female
% Transgender
% Do not identify as Male, Female, or Transgender
Ethnicity
% Caucasian
% African American
% Asian
% Hispanic/ Latino
% Other
History of Severe Psychiatric Illness
% Anxiety
% Depression
% Bipolar Depression
% Bipolar Manic
% Schizophrenia
% Borderline Personality Disorder
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Total Sample
62
16.1
75.8
4.8
3.2

32.9
4.8
6.5
1.6
3.2
74
80.6
29.0
16.1
32.3
17.7

CHAPTER III

RESULTS

Analysis
Missing values were recoded through the method of user-defined missing
variables. All statistical analyses were conducted through SPSS statistical software.

Reliability

Table 2 shows the internal consistency and descriptive statistics of the PNS-QR.
One sees that for the full scale, a Cronbach Alpha of .928 was attained. The alpha level

for the full scale was good. The alpha level for the subscales were in the acceptable,

except for Avolition. Avolition attained a .515 and this is not within the acceptable when
concerning reliability.
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Table 2: Reliability
PNS-QR Scale

PNS-QR Full scale
Positive Subscales
Hallucinations
Delusions
Thought Disorder
Bizarre Disorganization
Inappropriate affect
Negative Symptoms
Alogia
Affective flatting
Avolition
Anhedonia

Number of
items

Mean (SD)

Cronbach
Alpha

73

85.95 (29.2)

.928

6
9
7
8
10

6.4 (4.6)
6.4 (6.14)
7.2 (4.56)
10.65 (5.66)
14.01 (5.87)

.760
.846
.741
.831
.823

9
8
10
6

13.00 (6.68)
8.033 (5.23)
11.91 (4.41)
8.48 (4.59)

.898
.807
.515
.782

Construct Validity
A Factor Analysis was conducted on 73 questions. This analysis used a principal

component analysis extraction and a varimax rotation. Two components were obtained

explaining 81.71% of the variance. Component one comprises the subscales of
Hallucinations, Delusions, Thought Disorder, Bizarre Disorganization, Inappropriate

Affect, Alogia, Affective Flattening, and Blunting. Component one accounted for 69.83%
of the variance and had a total eigenvalue of 6.285. Component two comprises Avolition
and Anhedonia. It accounted for 11.88% of the variance with a total eigenvalue of 1.070.

Any criteria with an eigenvalue of less than 1 were not retained. A Kaiser- Meyer- Olkin
Measure of Sampling Adequacy attained a value of .834 and Bartlett's Test of Sphericity

had a significance of .000. Pairwise deletion was used during this analysis. This Factor

model expresses a divergence between component 1 and 2 based on variance. When

considering factor loadings Hallucinations, Delusions, and Thought Disorder have high
factor loadings at .820, .914, and .903, respectively. This suggests a similarity between
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these 3 variables. Avolition and Anhedonia had factor loadings of .916 and .844

respectively. This suggests a similarity between these 2 variables.

Table 3: Principal Component Analysis
PNS-QR sub scales

Factor 1

Factor 2

Communality

Hallucinations
Delusions
Thought Disorder
Bizarre Disorganization
Inappropriate Affect
Alogia
Affective FLBL
Avolition
Anhedonia

.820
.914
.903
.662
.747
.687
.674
.118
.348

.381
.158
.159
.636
.423
.593
.539
.916
.844

.818
.861
.840
.843
.737
.824
.745
.853
.833

Table 4: Independent Samples Test

________________________ Independent Samples Test________________
t-test for Equality of Means
Sig.
t
df
(2-tailed)

Hallucinations

Delusions
Thought
Disorder
Bizarre
Disorganization
Inappropriate
Affect
Alogia
Affective
Flattening
Avolition
Anhedonia

Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
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3.802
3.976
4.679
4.412
3.905
3.594
2.978
2.748
4.350
4.323
3.102
2.977
4.857
4.890
.945
1.004
1.996
2.010

47
40.613
48
32.704
46
27.519
47
27.862
42
25.085
45
31.497
46
33.719
44
39.927
48
41.834

.000
.000
.000
.000
.000
.001
.005
.010
.000
.000
.003
.006
.000
.000
.350
.321
.052
.051

During the analysis of this study there were multiple groups used to access positive and
negative symptoms. An independent sample t-test was performed to assess if there was

difference of the scales between individuals with schizophrenia and all other groups. In
this analysis all differences were significant between groups except for Anhedonia and

Avolition. Anhedonia and Avolition do not appear to be different between both
populations.

Table 5: Independent Samples Test- Area Under the Curve
Area Under the Curve

Test Result Variable(s)
PNSQR
McEvoy
Hallucinations
Delusions
Thought Disorder
Bizarre Disorganization
Inappropriate affect
Alogia
Affective Flattening
Avolition
Anhedonia

Area
.878
.053
.814
.833
.806
.865
.780
.797
.915
.744
.739

A test for Sensitivity and specificity was performed on the population. It indicates
that the McEvoy was the least successful scale at identifying the schizophrenia
population. It was the only one that could not distinguish between the two. However, the

McEvoy may not have been designed for this purpose.
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Table 6: Correlation of Subscales

Correlations
HA
DE
TD
BD
Pearson Correlation
1 .756** .739** .705**
Sig. (2-tailed)
.000
.000
.000
N
49
48
47
48
DE
Pearson Correlation .756**
1 .816** .641**
Sig. (2-tailed)
.000
.000
.000
N
48
50
47
48
TD
Pearson Correlation .739** .816**
1 .662**
Sig. (2-tailed)
.000
.000
.000
N
47
47
48
47
BD
Pearson Correlation .705** .641** .662**
1
Sig. (2-tailed)
.000
.000
.000
N
48
48
47
49
IA
Pearson Correlation .609** .648** .631** .666**
Sig. (2-tailed)
.000
.000
.000
.000
N
42
43
41
42
AG
Pearson Correlation .710** .550** .614** .772**
Sig. (2-tailed)
.000
.000
.000
.000
N
46
46
45
45
AF
Pearson Correlation .660** .605** .632** .746**
Sig. (2-tailed)
.000
.000
.000
.000
N
47
47
47
47
AN
Pearson Correlation .429**
.253
.276 .638**
Sig. (2-tailed)
.003
.093
.067
.000
N
45
45
45
45
AA
Pearson Correlation .559** .396** .349* .707**
Sig. (2-tailed)
.000
.005
.015
.000
N
48
49
48
48
**. Correlation is significant at the 0.01 level (2-tailed) .
HA

IA
.609**
.000
42
.648**
.000
43
.631**
.000
41
.666**
.000
42
1

44
.880**
.000
40
.629**
.000
41
.323*
.045
39
.578**
.000
43

AG
.710**
.000
46
.550**
.000
46
.614
.000
45
.772**
.000
45
.880**
.000
40
1

47
.743**
.000
45
.506**
.000
46
.639**
.000
46

AF
.660**
.000
47
.605**
.000
47
.632**
.000
47
.746**
.000
47
.629**
.000
41
.743**
.000
45
1

48
.532**
.000
45
.572**
.000
47

AN
.429**
.003
45
.253
.093
45
.276
.067
45
.638**
.000
45
.323*
.045
39
.506**
.000
46
.532**
.000
45
1
46
.706**
.000
45

AA
.559**
.000
48
.396**
.005
49
.349*
.015
48
.707**
.000
48
.578**
.000
43
.639**
.000
46
.572**
.000
47
.706**
.000
45
1
50

*. Correlation is significant at the 0.05 level (2-tailed).
Name Abbreviations: Hallucinations (HA), Delusions (DE), Thought Disorder (TD), Inappropriate Affect
(IA), Alogia (AG), Affective Flattening (AF), Avolition (AN), Anhedonia (AA)

A correlation was done between the subscales of the revised positive and negative

symptom scale. To see if there were any similarities between the scales. Avolition and
Anhedonia seem to be the most different compared to other scales. They both often attain

a lower Pearson Correlation in comparison to other subscales. Except for Bizarre
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Disorganization which is similarly correlated with all the subscales ranging between .6
and .7.

Table 7: Multiple Regression Between the PNS-QR and McEvoy Scales.
ANOVA
Sum of
F
Model
Squares
df
Mean Square
1
Regression
1277.908
1
1277.908
58.092
879.925
40
21.998
Residual
2157.833
41
Total
Regression
1406.692
2
751.141
39
Residual
2157.833
41
Total
3
Regression
1490.116
3
667.717
38
Residual
2157.833
41
Total
a. Dependent Variable: McEvoy
b. Predictors: (Constant), Bizarre disorganization
2

Sig.
.000b

703.346
19.260

36.518

.000c

496.705
17.572

28.268

.000d

The final portion of the study was to examine the construct validity of the PNSQR by correlating it with the McEvoy scale. The regression equation produced, F (3, 38)
= 28.268, p < .001 with an RA2 value of .658. Pairwise deletion was used during this

analysis.

20

Table 8: Excluded variables
Collinearity
Partial
_ Statistics
Correlation
Tolerance
-.112
.334
-.073
.334
-.102
.431
-.362
.484
-.383
.353
-.132
.314
-.362
.521
-.354
.440
.008
.302
.024
.314
.010
.395
-.101
.174
-.007
.280
-.333
.509
-.263
.393
-.060
.291
-.072
.291
-.091
.364
-.149
.172
.017
.279
-.100
.272

Model
Beta In
t
Sig.
1
Hallucinations
-.124b
-.704
.486
Delusions
-.081b
-.459
.649
-.099
b
-.639
.526
Thought Disorder
-.332b
-2.426
.020
Inappropriate Affect
-.411b
-2.586
.014
Alogia
-.150b
-.830
.412
Affective Flattening
Avolition
-.321b
-2.429
.020
-.341b
-2.366
.023
Anhedonia
.008c
.048
.962
2
Hallucinations
.025c
.147
.884
Delusions
.010c
.063
.950
Thought Disorder
-.143c
-.626
.535
Inappropriate Affect
-.008c
-.045
.965
Affective Flattening
Avolition
-.276c
-2.179
.036
-.247c
-1.678
.101
Anhedonia
-.062d
-.368
.715
3
Hallucinations
-.075d
-.442
.661
Delusions
-.084d
-.555
.582
Thought Disorder
-.200d
-.915
.366
Inappropriate Affect
.017d
.101
.920
Affective Flattening
-.106d
-.608
.547
Anhedonia
a. Dependent Variable: McEvoy
b. Predictors in the Model: (Constant), Bizarre Disorganization
c. Predictors in the Model: (Constant), Bizarre Disorganization, Alogia
d. Predictors in the Model: (Constant), Bizarre Disorganization, Alogia, Avolition
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CHAPTER IV

DISCUSSION

The purpose of this study was to revise the original PNS-Q as well as adjust scale
questions. The first aim assessed reliability of the total scale as well as the subscales. The

second aim assessed if there were distinct positive and negative components of the scale.
The last aim intended to examine if there was a linear relationship between the McEvoy
scale and the PNS-QR subscales.
When reflecting on the first aim, a minimum Cronbach Alpha of .70 was the

minimum acceptable value for internal consistency. The only scale that did not meet this
minimum criterion for internal consistency was the subscale Avolition. The low alpha
might suggest that the items represent a wider construct than perhaps just one.
Representative nature is related to validity. Well defined nature would be related to

factor analysis. or are not well defined from the other subscales within the revised

positive and negative symptoms scale. To optimize the usefulness of the scale it might be
imperative that these items be removed or rewritten in a way that reflects Avolition.
To understand whether this scale truly encompassed a binary positive and negative

component, a factor analysis was completed. This aim was partially supported by the

findings of this analysis. There were two components, one that composed of the positive
22

scales with the addition of Alogia and Affective Flattening. The other component

included Avolition and Anhedonia. Component 1 aligns with the awareness of abnormal
cognition and behavior, while component 2 is defined by loss of interest and motivation

in previously pleasurable activities. While these two components are not indictive of
completely separate positive and negative scales it might support a mixed

symptomatology among the participants in the study.
There were also partial findings to a linear relationship between the McEvoy scale
and the PNS-QR subscales. The model that was most closely related to the McEvoy scale

included Bizarre Disorganization, Alogia, and Avolition. As the McEvoy scale is a scale
that assesses awareness and the ability to recognize the need for treatment (McEvoy et al,
1993), these findings can help explain what symptomologies are most correlated with
insight. This may imply that when experiencing forms of severe psychiatric illness one

can understand more evident additions of strange behaviors or lack of ability to speak or
be motivated. While further examination would be needed, these subcategories may be
the most useful as a self-report measure in a clinical setting.
When considering the choice of analyses used in this study there were

considerations to be made. The internal consistency analysis was essential to confirm
construct validity. Similarly, the multiple regression to confirm a relationship between
the McEvoy scale and the PNS-QR subscales was important to establish a frame of

reference for insight in those scales. However, for the principal component analysis,
there was a choice between an exploratory factor analysis and a confirmatory factor

analysis. The confirmatory factor analysis was considered because there was an initial
idea of how the data should present itself. As there were preconceived concepts of
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positive and negative components as well as which questions belonged in a subscale.
However, for a preliminary analysis of this revised scale, it was important just to

examine the data in an unconfined analysis. This would allow for initial information

as to what concepts were accurately defined and could allow for later exploration of a

confirmatory factor analysis.
With this idea of a preliminary analysis it is important to understand what
could have been improved. There would need to be further examination and revisions

to understand how internal consistency would be affected with fewer questions. It is
also important to examine the inherent difficulties with self-report measures. Other

self-report measures have embedded scales to assess for response bias, positive

impression management, and/or negative impression management (van de Mortel,
2008). A future study where a response bias measure is included may allow for

exploration between positive and negative symptoms and how its implicated in

schizophrenia.
Lastly, there may have been limitations associated with the sample used in this

study. When considering the invariants from this preliminary analysis there might not

be evidence to suggest the findings may be applicable in other groups. The sample
was mostly Caucasian at 32.9%, majority female at 75.8%, with high rates of

depression and anxiety. This is in contrast to epidemiologic findings that state that
schizophrenia is often diagnosed in minority groups such as African American,
Latino/Hispanic groups, and various immigrants (Schwartz & Blankenship, 2014), as

well as a relatively equal prevalence between men and women (Li et al., 2016). The

size of the study may have affected findings as well. The sample size of 62 may not
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have been large enough for some of the analyses conducted. According to de Winter

(2009), the minimum recommended sample size of a factor analysis is 50. There
would need to be another analysis with more participants to understand if the findings
would be similar to other groups.

While further analysis needs to be obtained to assess the real-life implications

and uses of this measure, there were some promising findings. There was some partial
support of subscales Bizarre Disorganization, Alogia, and Avolition that were more
likely to be useful with individuals with improved insight, as well as partial findings

of distinct positive and negative symptoms within the scale. When considering future
research, this study would explore increasing diversity and examine the test questions

for definitive use and precision.
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Positive and Negative Symptoms Questionnaire Revised (PNS-QR)
Sponsor: N/A
PI: Amir Poreh Ph.D. PHONE #: (216) 687-3718

Informed Consent

You are being asked to take part in a research study which consists of answering a series
of questions.
You must be 18 years of age or older to take part. Please confirm that you are 18 years or
older.
□ Yes, I am 18 years or older
□ No, I am not 18 years or older

ABOUT THE RESEARCH
The purpose of the study is to update self-report measure PNS-QR that will available for
use by clinicians to measure individuals who may be candidate for diagnoses of severe
psychopathology. This research is attempting to establish a reliable measure that can
accurately access and predict schizophrenia. This will be done by updating and correcting
questions on the original PNS-QR and adding additional questions. This is done with the
intention of giving clinicians more informed insight into the schizophrenic symptoms of
their patients.
What is involved if you decide to take part in this research study?
Taking part in the study includes completing the questions on the PNS-QR. It takes about
30 minutes to complete. The questions cover a wide range of behaviors. It also has
questions about the use of alcohol and other drugs. Prior to completing the measure, you
will be asked (if applicable) about your mental health history. Also, you will be asked
what kind of medications you're currently being prescribed. The questionnaire can be
taken at any time after you agree using the web link. The results of the PNS-QR will be
stored in a HIPPA protected website and then the downloaded and identified to secure
encrypted hard drive. Once you complete the PANS-QR you will be asked if you are
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willing to retake the PNS-QR in a year. You may or may not chose to participate in this
follow-up study.

RISKS:
There are no physical risks involved with this study. Some people might find certain
questions distressing. If you experience such a distress you should call 211. The website
[/]http://www.211.org will help you locate mental health agencies in your region. You
may choose not to answer any question if you wish or discontinue the questionnaire. You
may end the study with no repercussions. There is a risk that an unauthorized data breach
might occur but we will make every effort to keep your answers safe.

BENEFITS
There are no direct benefits or compensation from completing this study.
COSTS & PAYMENT
There are no costs or payments to you for taking part in this study aside from
participating in a raffle.
PRIVACY
What will happen to your information collected for this research?
Personal names will not be collected during the study. However the volunteers emails
will be collected and be used to recruit them for the study. Toward the end of the study
volunteers will be asked if they're willing to retake the questionnaire at another time. If
they great to do the emails will remain within the HIPPA compliant system until they
complete the questionnaire once more. The email information will then be removed from
the database. Data will be collected on the HIPPA compliant web service and then stored
on a military grade hardware encrypted hard drive - APICRON A25-3PL256)

CONFLICT OF INTEREST
There are no conflicts of interest to report.
QUESTIONS
Who do you call if you have any questions or problems?
If you have any questions or problems, please contact Amir Poreh, PhD at (216) 687
3718 or a.poreh@csuohio.edu

TAKING PART IS OPTIONAL
What are your rights?
Taking part in this study is completely up to you. You may choose not to take part or may
leave the study at any time with no penalty.
Please read the following: “I understand that if I have any questions about my rights as a
research subject, I can contact the Cleveland State University Institutional Review Board
at (216) 687-3630.
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Consent:

Do You consent to participate in this study?
□ Yes, I consent to participate in this study.
□ No, I do not consent to participate in this study.

Initial call for volunteers:

This study is looking to assess the validity and reliability of a new measure of Severe
Psychopathology. We are inviting volunteers with and without mental health history to

participate in the study. The result of the PANS-QR will be stored in a HIPPA protected
website and then the downloaded and identified to secure encrypted hard drive. This

study is open to men and women between the ages of 18 and 65. The questionnaire
consists of 65 multiple choice questions and takes approximately 30 minutes to complete

and includes questions regarding mental health history as well as currently prescribed

medications

Email for the questionnaire link
A short time ago you received a request to participate in a study regarding the validity
and reliability of a new measure of personality functioning. The purpose of this study is

to gain better understanding of the reliability and validity of a new Schizophrenia scale.
We are inviting volunteers with and without mental health history to participate in the
study. The result of the personality inventory will be stored in a HIPPA protected website
and then the downloaded to secure encrypted hard drive. This study is open to men and

women between the ages of 18 and 65. The questionnaire consists of 65 multiple choice
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questions takes approximately 30 minutes to complete and includes questions regarding
mental health history as well as currently prescribed medications. Below is a link to the

questionnaire. If you agree to retake the questionnaire in a later time, we will keep you
email address. If not, we will remove your email once the study is completed.

Email for 1 year follow up
About a year ago you received a request to participate in a study regarding the validity
and reliability of a new measure of Schizophrenia. We are inviting volunteers with and

without mental health history to participate in the study. The result of the personality

inventory will be stored in a HIPPA protected website and then the downloaded and
identified to secure encrypted hard drive. This study is open to men and women between
the ages of 18 and 65. The questionnaire consists of 65 multiple choice questions takes

approximately 30 minutes to complete and includes questions regarding mental health

history as well as currently prescribed medications. Below is a link to the questionnaire.
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